Navigation Links
New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
Date:10/15/2007

PHILADELPHIA, Oct. 15 /PRNewswire-FirstCall/ -- Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) ulcerative colitis (UC) drug LIALDA(TM) (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis. These analyses of LIALDA's 303 trial, a long-term, Phase III, open-label 12-14 month extension study, are being presented this week at The American College of Gastroenterology (ACG) meeting in Philadelphia.

The primary endpoint of study 303 was safety and tolerability and findings -- that LIALDA is generally well tolerated in mild to moderate UC patients -- were presented at the British Society of Gastroenterology (BSG) meeting in Glasgow, Scotland in March 2007.

"Earlier studies showed that LIALDA is well-tolerated and effective at inducing remission in patients with active, mild to moderate UC. Post-hoc analysis of secondary endpoints provided evidence that LIALDA maintained remission in a variety of UC patients," said Gary R. Lichtenstein, M.D., director of the Center for Inflammatory Bowel Diseases at the Hospital of the University of Pennsylvania.

A summary of key scientific presentations of post-hoc analyses of secondary endpoints of study 303 follows.

Once or Twice Daily LIALDA for Mild vs. Moderate Ulcerative Colitis

Poster Presentation: Tuesday, October 16, 2007, Exhibit Hall B, #950

A post-hoc analysis of secondary endpoints from the long-term 303 study was performed to review the efficacy of LIALDA for maintaining remission in patients with mild versus moderate ulcerative colitis. In the 303 study, patients were randomized to receive LIALDA 2.4g/day (given once daily [QD]) or 2.4g/day (1.2g given twice daily [BID]). Study 303 defined patient remission using stringent clinical and endoscopic measures: modified UC Disease Activity Index (UC-DAI) score of less than or equal to 1 with score
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
7. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
8. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
9. 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
10. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
11. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 22, 2013 MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) ... about some recent company developments. As Medifirst continues to ... communication with shareholders. Integrating social media into its investor ... and will post updates on Twitter.  The Facebook homepage ... Says CEO Bruce J. ...
(Date:5/22/2013)... --  Life Line Screening  (LLS), a leading national ... of a unique partnership with MCM Solutions for ... a population health management organization. LLS will provide health ... important expanded services will help MCM and its clients ... cost of care when individuals are able to address ...
(Date:5/22/2013)... , May 22, 2013  Generex Biotechnology Corporation ... demonstrating the superiority of the AE37 breast cancer vaccine ... ( www.antigenexpress.com ). The presentations will be made at ... Oncology (ASCO) to be held in Chicago ... The presentation entitled " Booster inoculations of ...
Breaking Medicine Technology:Medifirst Solutions, Inc. Announces Update To Shareholders 2Life Line Screening and MCM Solutions for Better Health Announce New Partnership 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4
(Date:5/22/2013)... of the antidepressant Lexapro appears to help prevent ... study finds. The condition is known ... people with this condition may not develop noticeable ... blood supply, according to researchers from Duke University ... the researchers found that people taking the antidepressant ...
(Date:5/22/2013)... By Dennis Thompson HealthDay Reporter , , TUESDAY, ... Americans isn,t improving much, with about six in 10 ... in unhealthy behaviors like smoking, heavy drinking or not ... Tuesday by the U.S. Centers for Disease Control and ... of the lifestyle choices that have led to soaring ...
(Date:5/22/2013)... May 22 (HealthDay News) -- Roughly four in 10 ... pulmonary disease (COPD) actually do not have the lung ... Faulty diagnoses were made based on an evaluation of ... standard" disease test known as spirometry, which shows how ... amount of air they can exhale and how long ...
(Date:5/22/2013)... Atlanta, GA (PRWEB) May 22, 2013 ... marketing agency, JD Media Surge, LLC, E-Dentists.com has ... subjects. The blog will feature numerous topics of ... on treatment options and dental health. , ... element of dental Internet marketing. In addition to ...
(Date:5/22/2013)... Macedon, NY (PRWEB) May 22, 2013 ... other lean manufacturing improvements use the new Do-Done StepTracker ... coordination. “We use the Do-Done board to display the ... Each of our production cells and departments is listed ... top. As we start a project, the squares are ...
Breaking Medicine News(10 mins):Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 2Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 3Health News:Americans Still Making Unhealthy Choices: CDC 2Health News:Americans Still Making Unhealthy Choices: CDC 3Health News:COPD May Be Over-Diagnosed Among Uninsured 2Health News:Dental SEO Blog Launched by E-Dentists.com in Partnership with JD Media Surge, LLC 2Health News:Project Managers Organize Manufacturing Projects and Training with the New Steptracker Project Status Magnetic Whiteboards 2
... N.J., July 9 Red wine (resveratrol) pills appear to be ... to lead the way for patients and consumers to learn more ... do so. , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090709/LA44390 ) , ... of red wine pills, a local cardiology group says it will ...
... Today Americans United for Life (AUL) President & CEO Dr. ... members, urging them to ask Judge Sotomayor the "Top Ten" most ... the Court as the Senators prepare for her confirmation hearings to ... CEO Dr. Charmaine Yoest said, "It,s important for the American people ...
... As part of its Patient Voices series, ... is featuring the stories of people from across the country who ... Patient Voices seeks to give a glimpse into the life ... diverse as the disease itself, and include actress/model and Lupus Foundation ...
... 1 diabetes or having a preceding infection are associated with more ... 49 years old, according to a Finnish study. Furthermore, heart failure ... cancer malignancy with 16 times the risk of death in stroke ... group, said Jukka Putaala, M.D., who led the study. Risk of ...
... The President of the American Chemical Society, ... President Obama,s nomination of Francis Collins, M.D., Ph.D., to ... other time in recent memory has there been such a ... of science to deliver solutions to the grand challenges facing ...
... hits $42 million a year , THURSDAY, July 9 (HealthDay News) ... at least $42 million a year, a new study finds. , ... 100,000 young people annually, said Dr. Warren Lo, lead author of ... but there is growing concern about the cost of medical care ...
Cached Medicine News:Health News:Local Heart Doctors First in Nation to Announce Active Investigation of Red Wine (Resveratrol) Pills, Issue Consumer Precautions 2Health News:Local Heart Doctors First in Nation to Announce Active Investigation of Red Wine (Resveratrol) Pills, Issue Consumer Precautions 3Health News:Local Heart Doctors First in Nation to Announce Active Investigation of Red Wine (Resveratrol) Pills, Issue Consumer Precautions 4Health News:AUL President to Senate Judiciary Committee: Ask Top 10 Questions to Judge Sotomayor 2Health News:The New York Times Website Patient Voices Series Features People Affected by Lupus 2Health News:Stroke in Children Rare But Costly 2Health News:Stroke in Children Rare But Costly 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: